Coupling the radiopharmaceutical gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA) with PET/CT or PET/MRI has been a boon for prostate cancer imaging. But clinicians still need to be aware of some inherent shortcomings with the radiopharmaceutical, according to a research review published online April 12 in Urology. {read more here}